Added to YB: 2026-06-22
Pitch date: 2026-06-18
MEDCL.PA [neutral]
MedinCell S.A.
-12.81%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
Market Cap
EUR 879.8M
Pitch Price
EUR 24.98
Price Target
N/A
Dividend
N/A
EV/EBITDA
-44.97
P/E
-26.06
EV/Sales
35.71
Sector
Pharmaceuticals
Category
growth
Medincell (MEDCL France): The upcoming ramp-up should sustain the momentum
MEDCL.PA (update): FY rev €24.3m (down on prior-yr one-off milestones), but recurring royalties shifting higher-margin: UZEDY €9.3m (+42% yoy) on Teva +54% sales; partnership rev €10.2m (€6.4m AbbVie). Op loss €20.8m, net loss €31.3m, €24.6m burn; €84.8m cash post €48.2m raise. UZEDY now approved in bipolar; olanzapine LAI FDA decision Q4 2026; AbbVie first clinical pushed to 2027. 10+ programs add optionality.
Read full article (2 min)